Board of Directors:

Alan Lewis, PhD Chairman

Dr. Lewis is currently the President and Chief Executive Officer of Ambit Biosciences. Previously, he served as the President and CEO of the Juvenile Diabetes Research Foundation from January 2009, and as President, CEO, and Director of Novocell, Inc. from February 2006. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases. He then served as President of the Signal Research Division at Celgene. Dr. Lewis previously held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis also currently serves as a Director of BioMarin Pharmaceutical, Inc., and BIOCOM. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.